Early stopping of clinical trials

Breast Cancer Research

Volumn 7, Issue 5, 2005, Pages 181-183

  Cuzick, Jack ^a   Howell, Anthony ^b   Forbes, John ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; EXEMESTANE; HORMONE; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL RESEARCH; CLINICAL TRIAL; DEATH; DRUG SAFETY; DRUG WITHDRAWAL; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL ETHICS; PROGNOSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAFETY; TIME FACTORS;

EID: 25844470999     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr1280     Document Type: Article

References (10)

1. Holmberg L, Anderson H; HABITS steering and data monitoring committees: HABITS (hormonal replacement therapy after breast cancer - is it safe?): a randomised comparison: trial stopped. Lancet 2004, 363:453-455.
2. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer - results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analysis. Cancer 2003, 98:1802-1810.
3. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, Hamed A, Howell A, Powles T; IBIS Investigators: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002, 360:817-824.
4. The ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
5. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998, 90:1371-1388.
6. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
7. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione MM, Tu D, Shepherd LE, Pater JL: Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in post-menopausal women with early stage breast cancer. J Clin Oncol 2004, 22(14S, 15 July Suppl): 84.
8. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, et al.: Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350: 1081-1092.
9. Thürlimann B: Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. BIG 1-98: a prospective randomized double-blind phase III study. Breast 2005, 14(suppl 1):abstract S4.
10. ASCO - Herceptin effective adjuvant therapy for breast cancer http://www.asco.org/ac/1,1003,_12-002123-00_18-0039602-00_19- 0039603-00_20-001,00.asp#TOP